Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma
Objectives Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA...
Saved in:
Published in | European radiology Vol. 31; no. 11; pp. 8649 - 8661 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.11.2021
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 0938-7994 1432-1084 1432-1084 |
DOI | 10.1007/s00330-021-07729-9 |
Cover
Abstract | Objectives
Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).
Methods
We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.
Results
SW-RFA showed a higher rate of achieving an adequate safety margin (
p
= 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (
p
< 0.001) and better overall survival (
p
= 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030–0.607,
p
= 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152–0.747,
p
= 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (
p
= 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (
p
= 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%,
p
= 1.000).
Conclusions
The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.
Key Points
•
Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma.
•
Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC.
•
Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation. |
---|---|
AbstractList | ObjectivesRadiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).MethodsWe retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.ResultsSW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030–0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152–0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000).ConclusionsThe switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.Key Points• Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma.• Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC.• Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation. Objectives Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA). Methods We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison. Results SW-RFA showed a higher rate of achieving an adequate safety margin ( p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates ( p < 0.001) and better overall survival ( p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030–0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152–0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate ( p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C ( p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000). Conclusions The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival. Key Points • Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation. Radiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).OBJECTIVESRadiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.METHODSWe retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.SW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030-0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152-0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000).RESULTSSW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030-0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152-0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000).The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.CONCLUSIONSThe switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.• Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.KEY POINTS• Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation. Radiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA). We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison. SW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030-0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152-0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000). The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival. • Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation. |
Author | Hsieh, Yi-Chung Lin, Chen-Chun Lin, Shi-Ming Lui, Kar-Wai Teng, Wei Chen, Wei-Ting Cheng, Ya-Ting |
Author_xml | – sequence: 1 givenname: Chen-Chun surname: Lin fullname: Lin, Chen-Chun organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University – sequence: 2 givenname: Kar-Wai surname: Lui fullname: Lui, Kar-Wai organization: Department of Medical Imaging & Intervention, Linkou Chang Gung Memorial Hospital, Chang Gung University – sequence: 3 givenname: Wei-Ting surname: Chen fullname: Chen, Wei-Ting organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University – sequence: 4 givenname: Yi-Chung surname: Hsieh fullname: Hsieh, Yi-Chung organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University – sequence: 5 givenname: Ya-Ting surname: Cheng fullname: Cheng, Ya-Ting organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University – sequence: 6 givenname: Wei surname: Teng fullname: Teng, Wei organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University – sequence: 7 givenname: Shi-Ming orcidid: 0000-0001-7527-6181 surname: Lin fullname: Lin, Shi-Ming email: lsmpaicyto@cloud.cgmh.org.tw, lsmpaicyto@gmail.com organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33895858$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1rFTEYhYNU7G31D7iQATduom8-5iZZSvELCi7Udcgk79ymzCTXZMZSf725vS1CF10FwnMO57znjJyknJCQ1wzeMwD1oQIIARQ4o6AUN9Q8IxsmBacMtDwhGzBCU2WMPCVntV4DgGFSvSCnQmjT615vyP7HTVz8VUy7bs4p7_PkSldciHks-HvF5G87N0xuiTl1cd6X_AdrN-W0owuWucvr4vPcvvLYzRjiOtMa_2LornDvluxxmtaDpXfFx5Rn95I8H91U8dX9e05-ff708-Irvfz-5dvFx0vqheoXKgYMiP1WmV5uWZA-SI2coe9hGIPiXDoIAmDotfNuy3gQrQ_rQeLWKx_EOXl39G2RW4-62DnWQxyXMK_V8p5pJRkX0NC3j9DrvJbU0jVKc224EbxRb-6pdWhN7b7E2ZVb-3DLBugj4EuuteBofVzuDrcUFyfLwB5ms8fZbJvN3s1mTZPyR9IH9ydF4iiqDU47LP9jP6H6B_0vq8w |
CitedBy_id | crossref_primary_10_2147_JHC_S268300 crossref_primary_10_1111_liv_15052 |
Cites_doi | 10.1371/journal.pone.0161980 10.1148/radiol.13130940 10.1148/radiol.2411051271 10.1016/j.jvir.2011.02.005 10.1159/000343877 10.1097/01.sla.0000201480.65519.b8 10.1016/j.jvir.2014.08.027 10.1016/S2468-1253(18)30029-3 10.1002/hep.20933 10.1097/RLI.0b013e3180661aad 10.1007/s00270-012-0377-1 10.1016/j.jvir.2016.02.031 10.1016/j.jvir.2007.05.010 10.3748/wjg.v21.i10.2997 10.1007/s00330-019-06575-0 10.1016/j.jhep.2012.09.020 10.1148/radiol.14132958 10.1002/hep.21164 10.1200/JCO.2012.42.9936 10.1016/j.jvir.2008.09.021 10.2214/AJR.04.1346 10.21037/jgo.2019.01.34 10.1159/000367755 10.1038/ajg.2011.425 10.1016/j.jvir.2009.09.003 10.1080/02656736.2018.1440017 10.1002/cncr.25314 10.1016/j.jhep.2016.07.010 10.1148/radiol.2442060826 10.3348/kjr.2012.13.1.34 10.1245/s10434-011-1673-8 10.1148/radiol.13121736 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.1016/j.ejrad.2013.12.015 10.1002/hep.29913 10.1016/j.suronc.2007.08.002 10.1007/s12072-017-9799-9 10.1097/SLA.0000000000001797 10.1016/j.jhep.2018.02.026 10.1016/j.jhep.2017.10.004 10.1016/j.hpb.2020.01.008 10.1016/j.jhep.2018.03.019 |
ContentType | Journal Article |
Copyright | European Society of Radiology 2021 European Society of Radiology 2021. 2021. European Society of Radiology. |
Copyright_xml | – notice: European Society of Radiology 2021 – notice: European Society of Radiology 2021. – notice: 2021. European Society of Radiology. |
DBID | AAYXX CITATION NPM 3V. 7QO 7RV 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ P5Z P62 P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 |
DOI | 10.1007/s00330-021-07729-9 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed ProQuest Central Student Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Advanced Technologies & Aerospace Database Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Central Student MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-1084 |
EndPage | 8661 |
ExternalDocumentID | 33895858 10_1007_s00330_021_07729_9 |
Genre | Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 04C 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 6PF 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARAPS ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGLVJ BGNMA BHPHI BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECF ECT EIHBH EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I-F I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P62 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7R Z7U Z7X Z7Y Z7Z Z82 Z83 Z85 Z87 Z88 Z8M Z8O Z8R Z8S Z8T Z8V Z8W Z8Z Z91 Z92 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG ADKFA AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT NPM 7QO 7XB 8FD 8FK ABRTQ AZQEC DWQXO FR3 GNUQQ K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI 7X8 |
ID | FETCH-LOGICAL-c375t-3bedee56795461d4cd48e21ec50bfd7224a0d300b58aca612d38581504e6c7cd3 |
IEDL.DBID | U2A |
ISSN | 0938-7994 1432-1084 |
IngestDate | Fri Sep 05 07:20:05 EDT 2025 Fri Jul 25 19:06:03 EDT 2025 Thu Apr 03 07:09:50 EDT 2025 Tue Jul 01 03:08:24 EDT 2025 Thu Apr 24 23:02:35 EDT 2025 Fri Feb 21 02:47:36 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Retrospective studies Propensity score Humans Liver neoplasms Ablation techniques |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c375t-3bedee56795461d4cd48e21ec50bfd7224a0d300b58aca612d38581504e6c7cd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-7527-6181 |
PMID | 33895858 |
PQID | 2582892932 |
PQPubID | 54162 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2518741230 proquest_journals_2582892932 pubmed_primary_33895858 crossref_citationtrail_10_1007_s00330_021_07729_9 crossref_primary_10_1007_s00330_021_07729_9 springer_journals_10_1007_s00330_021_07729_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-11-01 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationTitle | European radiology |
PublicationTitleAbbrev | Eur Radiol |
PublicationTitleAlternate | Eur Radiol |
PublicationYear | 2021 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | Peng, Zhang, Chen (CR8) 2008; 17 Huang, Yu, Liang (CR41) 2014; 83 Wang, Sofocleous, Erinjeri (CR29) 2013; 36 Marrero, Kulik, Sirlin (CR3) 2018; 68 Lonjon, Porcher, Ergina, Fouet, Boutron (CR39) 2017; 265 Brace, Sampson, Hinshaw, Sandhu, Lee (CR15) 2009; 20 Omata, Cheng, Kokudo (CR1) 2017; 11 Zhang, Liang, Chen (CR10) 2007; 244 Kamal, Elmoety, Rostom, Shater, Lashen (CR35) 2019; 10 Lee, Lee, Yoon (CR20) 2012; 13 CR34 Peng, Zhang, Chen (CR11) 2013; 31 Morimoto, Numata, Kondou, Nozaki, Morita, Tanaka (CR38) 2010; 116 Sun, Cheng, Wu (CR32) 2015; 21 Teratani, Yoshida, Shiina (CR5) 2006; 43 Vietti Violi, Duran, Guiu (CR36) 2018; 3 Park, Kim, Rhim, Lim, Lee, Choi (CR13) 2011; 22 CR2 Lee, Kang, Lim (CR4) 2020; 30 Lee, Han, Kim (CR16) 2007; 42 Kim, Won, Shin (CR14) 2011; 18 Bruix, Sherman (CR21) 2005; 42 Lee, Kang, Cha (CR40) 2018; 69 Shiina, Tateishi, Arano (CR7) 2012; 107 Lee, Lee, Lee (CR31) 2014; 270 Ahmed, Solbiati, Brace (CR25) 2014; 273 Choi, Lee, Lee (CR17) 2016; 11 Teng, Liu, Lin (CR24) 2015; 4 Hocquelet, Trillaud, Frulio (CR30) 2016; 27 Loriaud, Denys, Seror (CR42) 2018; 34 Laeseke, Sampson, Haemmerich (CR23) 2006; 241 Kim, Lim, Rhim (CR6) 2013; 58 Ahmed, Solbiati, Brace (CR27) 2014; 25 Cho, Rhim, Ahn, Kim, Lim (CR12) 2006; 186 Hocquelet, Aube, Rode (CR26) 2017; 66 D’Agostino (CR28) 1998; 17 Chen, Li, Zheng (CR9) 2006; 243 Nault, Sutter, Nahon, Ganne-Carrie, Seror (CR33) 2017; 68 Laeseke, Sampson, Frey (CR22) 2007; 18 Lin, Cheng, Chen, Lin (CR18) 2016; 5 Kang, Yoon, Jeong (CR37) 2009; 20 Woo, Lee, Yoon (CR19) 2013; 268 PF Laeseke (7729_CR22) 2007; 18 7729_CR34 G Lonjon (7729_CR39) 2017; 265 DH Lee (7729_CR31) 2014; 270 PF Laeseke (7729_CR23) 2006; 241 MJ Park (7729_CR13) 2011; 22 JM Lee (7729_CR16) 2007; 42 JH Kim (7729_CR14) 2011; 18 CC Lin (7729_CR18) 2016; 5 A Hocquelet (7729_CR30) 2016; 27 S Shiina (7729_CR7) 2012; 107 A Kamal (7729_CR35) 2019; 10 JC Nault (7729_CR33) 2017; 68 JA Marrero (7729_CR3) 2018; 68 M Omata (7729_CR1) 2017; 11 MW Lee (7729_CR4) 2020; 30 A Hocquelet (7729_CR26) 2017; 66 W Teng (7729_CR24) 2015; 4 J Lee (7729_CR20) 2012; 13 J Bruix (7729_CR21) 2005; 42 M Ahmed (7729_CR25) 2014; 273 S Huang (7729_CR41) 2014; 83 A Loriaud (7729_CR42) 2018; 34 ZW Peng (7729_CR8) 2008; 17 M Morimoto (7729_CR38) 2010; 116 YK Cho (7729_CR12) 2006; 186 M Ahmed (7729_CR27) 2014; 25 AX Sun (7729_CR32) 2015; 21 MS Chen (7729_CR9) 2006; 243 YJ Zhang (7729_CR10) 2007; 244 RB D’Agostino Jr (7729_CR28) 1998; 17 X Wang (7729_CR29) 2013; 36 JW Choi (7729_CR17) 2016; 11 YS Kim (7729_CR6) 2013; 58 7729_CR2 ZW Peng (7729_CR11) 2013; 31 SG Kang (7729_CR37) 2009; 20 S Lee (7729_CR40) 2018; 69 T Teratani (7729_CR5) 2006; 43 S Woo (7729_CR19) 2013; 268 CL Brace (7729_CR15) 2009; 20 N Vietti Violi (7729_CR36) 2018; 3 |
References_xml | – volume: 11 start-page: e0161980 year: 2016 ident: CR17 article-title: Switching monopolar radiofrequency ablation using a separable cluster electrode in patients with hepatocellular carcinoma: a prospective study publication-title: PLoS One doi: 10.1371/journal.pone.0161980 – volume: 270 start-page: 900 year: 2014 end-page: 909 ident: CR31 article-title: Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis publication-title: Radiology doi: 10.1148/radiol.13130940 – volume: 241 start-page: 116 year: 2006 end-page: 124 ident: CR23 article-title: Multiple-electrode radiofrequency ablation creates confluent areas of necrosis: in vivo porcine liver results publication-title: Radiology doi: 10.1148/radiol.2411051271 – volume: 22 start-page: 771 year: 2011 end-page: 779 ident: CR13 article-title: A comparison of US-guided percutaneous radiofrequency ablation of medium-sized hepatocellular carcinoma with a cluster electrode or a single electrode with a multiple overlapping ablation technique publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2011.02.005 – volume: 4 start-page: 26 year: 2015 end-page: 38 ident: CR24 article-title: Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation publication-title: Liver Cancer doi: 10.1159/000343877 – volume: 243 start-page: 321 year: 2006 end-page: 328 ident: CR9 article-title: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma publication-title: Ann Surg doi: 10.1097/01.sla.0000201480.65519.b8 – ident: CR2 – volume: 25 start-page: 1691 year: 2014 end-page: 1705 e1694 ident: CR27 article-title: Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2014.08.027 – volume: 3 start-page: 317 year: 2018 end-page: 325 ident: CR36 article-title: Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(18)30029-3 – volume: 42 start-page: 1208 year: 2005 end-page: 1236 ident: CR21 article-title: Management of hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 42 start-page: 676 year: 2007 end-page: 683 ident: CR16 article-title: Multiple-electrode radiofrequency ablation of in vivo porcine liver: comparative studies of consecutive monopolar, switching monopolar versus multipolar modes publication-title: Invest Radiol doi: 10.1097/RLI.0b013e3180661aad – volume: 36 start-page: 166 year: 2013 end-page: 175 ident: CR29 article-title: Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-012-0377-1 – volume: 27 start-page: 1038 year: 2016 end-page: 1045 e1032 ident: CR30 article-title: Three-dimensional measurement of hepatocellular carcinoma ablation zones and margins for predicting local tumor progression publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2016.02.031 – volume: 18 start-page: 1005 year: 2007 end-page: 1010 ident: CR22 article-title: Multiple-electrode radiofrequency ablation: comparison with a conventional cluster electrode in an in vivo porcine kidney model publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2007.05.010 – volume: 21 start-page: 2997 year: 2015 end-page: 3004 ident: CR32 article-title: Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i10.2997 – volume: 30 start-page: 2391 year: 2020 end-page: 2400 ident: CR4 article-title: Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival publication-title: Eur Radiol doi: 10.1007/s00330-019-06575-0 – volume: 58 start-page: 89 year: 2013 end-page: 97 ident: CR6 article-title: Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors publication-title: J Hepatol doi: 10.1016/j.jhep.2012.09.020 – volume: 273 start-page: 241 year: 2014 end-page: 260 ident: CR25 article-title: Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update publication-title: Radiology doi: 10.1148/radiol.14132958 – volume: 43 start-page: 1101 year: 2006 end-page: 1108 ident: CR5 article-title: Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations publication-title: Hepatology doi: 10.1002/hep.21164 – volume: 31 start-page: 426 year: 2013 end-page: 432 ident: CR11 article-title: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.9936 – volume: 20 start-page: 118 year: 2009 end-page: 124 ident: CR15 article-title: Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2008.09.021 – volume: 186 start-page: S269 year: 2006 end-page: S274 ident: CR12 article-title: Percutaneous radiofrequency ablation therapy of hepatocellular carcinoma using multitined expandable electrodes: comparison of subcapsular and nonsubcapsular tumors publication-title: AJR Am J Roentgenol doi: 10.2214/AJR.04.1346 – volume: 10 start-page: 562 year: 2019 end-page: 571 ident: CR35 article-title: Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial publication-title: J Gastrointest Oncol doi: 10.21037/jgo.2019.01.34 – volume: 5 start-page: 8 year: 2016 end-page: 20 ident: CR18 article-title: The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona Clinic Liver Cancer stage A to B2 publication-title: Liver Cancer doi: 10.1159/000367755 – volume: 107 start-page: 569 year: 2012 end-page: 577 ident: CR7 article-title: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.425 – volume: 20 start-page: 1570 year: 2009 end-page: 1577 ident: CR37 article-title: Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2009.09.003 – volume: 34 start-page: 1171 year: 2018 end-page: 1178 ident: CR42 article-title: Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems publication-title: Int J Hyperthermia doi: 10.1080/02656736.2018.1440017 – volume: 116 start-page: 5452 year: 2010 end-page: 5460 ident: CR38 article-title: Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization publication-title: Cancer doi: 10.1002/cncr.25314 – volume: 66 start-page: 67 year: 2017 end-page: 74 ident: CR26 article-title: Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC publication-title: J Hepatol doi: 10.1016/j.jhep.2016.07.010 – volume: 244 start-page: 599 year: 2007 end-page: 607 ident: CR10 article-title: Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial publication-title: Radiology doi: 10.1148/radiol.2442060826 – volume: 13 start-page: 34 year: 2012 end-page: 43 ident: CR20 article-title: Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas publication-title: Korean J Radiol doi: 10.3348/kjr.2012.13.1.34 – ident: CR34 – volume: 18 start-page: 1624 year: 2011 end-page: 1629 ident: CR14 article-title: Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-1673-8 – volume: 268 start-page: 589 year: 2013 end-page: 600 ident: CR19 article-title: Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results publication-title: Radiology doi: 10.1148/radiol.13121736 – volume: 17 start-page: 2265 year: 1998 end-page: 2281 ident: CR28 article-title: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B – volume: 83 start-page: 552 year: 2014 end-page: 558 ident: CR41 article-title: Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long-term follow-up publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2013.12.015 – volume: 68 start-page: 723 year: 2018 end-page: 750 ident: CR3 article-title: Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases publication-title: Hepatology doi: 10.1002/hep.29913 – volume: 17 start-page: 23 year: 2008 end-page: 31 ident: CR8 article-title: Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma publication-title: Surg Oncol doi: 10.1016/j.suronc.2007.08.002 – volume: 11 start-page: 317 year: 2017 end-page: 370 ident: CR1 article-title: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update publication-title: Hepatol Int doi: 10.1007/s12072-017-9799-9 – volume: 265 start-page: 901 year: 2017 end-page: 909 ident: CR39 article-title: Potential pitfalls of reporting and bias in observational studies with propensity score analysis assessing a surgical procedure: a methodological systematic review publication-title: Ann Surg doi: 10.1097/SLA.0000000000001797 – volume: 69 start-page: 70 year: 2018 end-page: 78 ident: CR40 article-title: Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes publication-title: J Hepatol doi: 10.1016/j.jhep.2018.02.026 – volume: 68 start-page: 783 year: 2017 end-page: 797 ident: CR33 article-title: Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations publication-title: J Hepatol doi: 10.1016/j.jhep.2017.10.004 – volume: 11 start-page: e0161980 year: 2016 ident: 7729_CR17 publication-title: PLoS One doi: 10.1371/journal.pone.0161980 – volume: 3 start-page: 317 year: 2018 ident: 7729_CR36 publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(18)30029-3 – volume: 20 start-page: 1570 year: 2009 ident: 7729_CR37 publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2009.09.003 – volume: 83 start-page: 552 year: 2014 ident: 7729_CR41 publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2013.12.015 – volume: 243 start-page: 321 year: 2006 ident: 7729_CR9 publication-title: Ann Surg doi: 10.1097/01.sla.0000201480.65519.b8 – volume: 58 start-page: 89 year: 2013 ident: 7729_CR6 publication-title: J Hepatol doi: 10.1016/j.jhep.2012.09.020 – volume: 265 start-page: 901 year: 2017 ident: 7729_CR39 publication-title: Ann Surg doi: 10.1097/SLA.0000000000001797 – volume: 34 start-page: 1171 year: 2018 ident: 7729_CR42 publication-title: Int J Hyperthermia doi: 10.1080/02656736.2018.1440017 – volume: 244 start-page: 599 year: 2007 ident: 7729_CR10 publication-title: Radiology doi: 10.1148/radiol.2442060826 – volume: 18 start-page: 1624 year: 2011 ident: 7729_CR14 publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-1673-8 – volume: 273 start-page: 241 year: 2014 ident: 7729_CR25 publication-title: Radiology doi: 10.1148/radiol.14132958 – volume: 27 start-page: 1038 year: 2016 ident: 7729_CR30 publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2016.02.031 – volume: 186 start-page: S269 year: 2006 ident: 7729_CR12 publication-title: AJR Am J Roentgenol doi: 10.2214/AJR.04.1346 – volume: 4 start-page: 26 year: 2015 ident: 7729_CR24 publication-title: Liver Cancer doi: 10.1159/000343877 – volume: 68 start-page: 783 year: 2017 ident: 7729_CR33 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.10.004 – volume: 20 start-page: 118 year: 2009 ident: 7729_CR15 publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2008.09.021 – volume: 68 start-page: 723 year: 2018 ident: 7729_CR3 publication-title: Hepatology doi: 10.1002/hep.29913 – volume: 43 start-page: 1101 year: 2006 ident: 7729_CR5 publication-title: Hepatology doi: 10.1002/hep.21164 – volume: 241 start-page: 116 year: 2006 ident: 7729_CR23 publication-title: Radiology doi: 10.1148/radiol.2411051271 – volume: 66 start-page: 67 year: 2017 ident: 7729_CR26 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.07.010 – volume: 25 start-page: 1691 year: 2014 ident: 7729_CR27 publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2014.08.027 – volume: 30 start-page: 2391 year: 2020 ident: 7729_CR4 publication-title: Eur Radiol doi: 10.1007/s00330-019-06575-0 – volume: 17 start-page: 23 year: 2008 ident: 7729_CR8 publication-title: Surg Oncol doi: 10.1016/j.suronc.2007.08.002 – ident: 7729_CR34 doi: 10.1016/j.hpb.2020.01.008 – volume: 116 start-page: 5452 year: 2010 ident: 7729_CR38 publication-title: Cancer doi: 10.1002/cncr.25314 – volume: 42 start-page: 676 year: 2007 ident: 7729_CR16 publication-title: Invest Radiol doi: 10.1097/RLI.0b013e3180661aad – volume: 13 start-page: 34 year: 2012 ident: 7729_CR20 publication-title: Korean J Radiol doi: 10.3348/kjr.2012.13.1.34 – volume: 268 start-page: 589 year: 2013 ident: 7729_CR19 publication-title: Radiology doi: 10.1148/radiol.13121736 – volume: 270 start-page: 900 year: 2014 ident: 7729_CR31 publication-title: Radiology doi: 10.1148/radiol.13130940 – volume: 22 start-page: 771 year: 2011 ident: 7729_CR13 publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2011.02.005 – volume: 69 start-page: 70 year: 2018 ident: 7729_CR40 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.02.026 – volume: 21 start-page: 2997 year: 2015 ident: 7729_CR32 publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i10.2997 – volume: 10 start-page: 562 year: 2019 ident: 7729_CR35 publication-title: J Gastrointest Oncol doi: 10.21037/jgo.2019.01.34 – volume: 11 start-page: 317 year: 2017 ident: 7729_CR1 publication-title: Hepatol Int doi: 10.1007/s12072-017-9799-9 – volume: 42 start-page: 1208 year: 2005 ident: 7729_CR21 publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 18 start-page: 1005 year: 2007 ident: 7729_CR22 publication-title: J Vasc Interv Radiol doi: 10.1016/j.jvir.2007.05.010 – volume: 17 start-page: 2265 year: 1998 ident: 7729_CR28 publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B – volume: 31 start-page: 426 year: 2013 ident: 7729_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.9936 – volume: 107 start-page: 569 year: 2012 ident: 7729_CR7 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.425 – ident: 7729_CR2 doi: 10.1016/j.jhep.2018.03.019 – volume: 5 start-page: 8 year: 2016 ident: 7729_CR18 publication-title: Liver Cancer doi: 10.1159/000367755 – volume: 36 start-page: 166 year: 2013 ident: 7729_CR29 publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-012-0377-1 |
SSID | ssj0009147 |
Score | 2.3682847 |
Snippet | Objectives
Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the... Radiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative... ObjectivesRadiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 8649 |
SubjectTerms | Ablation Coagulation Confidence intervals Diagnostic Radiology Failure rates Hepatobiliary-Pancreas Hepatocellular carcinoma Imaging Internal Medicine Interventional Radiology Liver cancer Medicine Medicine & Public Health Neuroradiology Patients Progressions Radio frequency Radiofrequency ablation Radiology Safety margins Survival Switching Tumors Ultrasound |
SummonAdditionalLinks | – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLfYkKZdEB-DdRRkJG6bReLYSXxCCFEmpHGBSb1F_gpUauPSpkLjr-c9x22FJnpN7MR6z_b7fj9C3lYeW6gow4QRYKAYnjPNHR48p4xttcpiy_ybr-X1rfgyldPkcFuntMrtnRgvahcs-sjfcYzvgCwv-PvlL4aoURhdTRAaR-RhzkHWYqX45PO-6W4eAcbAaK9ZpZRIRTOxdA5BzDKGCQoZKphM_SuY7mmb9yKlUQBNHpNHSXOkHwZWPyEPfPeUnNyk2Pgzsvz2e9bHzEgKa0XsA72iK-1moV0N-dJ3VJsh9Y3Ooi_Br-k8dD8YXs80bHqgBDwKLcWI-2bB1rM_3tGfILH6gB5-TFmlFtGHurDQZ-R28un7x2uW8BSYLSrZs8J4570sKyVFmTthnag9z72VmWldBcJcZ67IMiNrbTWoPg6jhqAxCl_ayrriOTnuQufPCRWmVb6tZaudipE3ZbiS3JW1LaUs1IjkW2I2NjUbR8yLebNrkxwZ0AADmsiABuZc7uYsh1YbB0ePtzxq0rFbN_tNMiJvdq_hwCCNdOfDBscgDCEI7GxEXgy83f0O7HUF9lM9IldbZu8__v-1XBxey0tyynGjxQrGMTnuVxv_ClSZ3ryO-_UvhDbvGg priority: 102 providerName: ProQuest |
Title | Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma |
URI | https://link.springer.com/article/10.1007/s00330-021-07729-9 https://www.ncbi.nlm.nih.gov/pubmed/33895858 https://www.proquest.com/docview/2582892932 https://www.proquest.com/docview/2518741230 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1ra9swUKwtjH0Z7Z7Z2qDBvm0CW5Zs62NSkpaNhrEtkH0yenkLtHZJHEb763cnP8roNtgXC2y9rDvp7nQvQt5mHkOoKMOEESCgGB4zzR1uPKeMLbWKQsj8i0V6vhQfVnLVOYVte2v3XiUZTurB2Q3TjkUMTQoiZAmZ2iMHEuNJARYv-eQu1G4c0oqBqJ6zTCnRucr8uY_fydE9HvOefjSQnfkhedzxi3TSAviIPPDVE_LwotOIPyXXX36um2APSQGhMOOB3tCNduu63LRW0jdUm9bgja7DDYLf0su6-s7wUKb1roHfh1d1SVHPvrti2_Wtd_QH0Kmmxnt9NFSlFnMOVfWVfkaW89nX03PWZVFgNslkwxLjnfcyzZQUaeyEdSL3PPZWRqZ0GZBwHbkkiozMtdXA8DjUFQKfKHxqM-uS52S_qiv_klBhSuXLXJbaqaBvU4YryV2a21TKRI1I3C9mYbsQ45jp4rIYgiMHABQAgCIAoIA274Y2122AjX_WPu5hVHSbbVvwMBXgW_iIvBk-wzbBNdKVr3dYB5MPApmORuRFC9thOJDSFUhN-Yi874F91_nf5_Lq_6q_Jo84Il7wYzwm-81m50-AoWnMmOxlqwye-fxsTA4m8-l0geXZt48zKKezxafP44DjvwB2VvJy |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiDcLBYwEJ7BIHDuJDxXi0WpLuysErdRb8CuwUpssu1lV5cfx25hxkl2hit56TWwnmodn7Hl8hLzMPLZQUYYJI-CAYnjMNHeoeE4ZW2oVhZb540k6OhKfj-XxBvnT18JgWmW_J4aN2tUW78jfcozvgC1P-LvZL4aoURhd7SE0dAet4LZDi7GusGPfn5_BEW6xvfcJ-P2K892dw48j1qEMMJtksmGJ8c57mWZKijR2wjqRex57KyNTugxMnI5cEkVG5tpqcAgcxtLAjxI-tZl1Cax7jWwKvEAZkM0PO5MvX9dtf-MAcRYp2FYypURXthOK9xBGLWKYIhGhi8vUv6bxgr97IVYbTODubXKr813p-1bY7pANX90l18dddP4emX07mzYhN5MCtRB9Qc_pXLtpXc7bjO1zqk2bfEen4TbDL-hJXf1gaCBovWyAF_CoLinG_JenbDH97R39CTazqTHGgEmz1CL-UVWf6vvk6Epo_YAMqrryjwgVplS-zGWpnQqxP2W4ktyluU2lTNSQxD0xC9u1O0fUjZNi1ag5MKAABhSBAQXMeb2aM2ubfVw6eqvnUdEp_qJYi-mQvFi9BpVFGunK10scg0CI4DJEQ_Kw5e3qcwk4kHCCy4fkTc_s9eL__5fHl__Lc3JjdDg-KA72JvtPyE2OQhfqKbfIoJkv_VNwrBrzrJNeSr5ftcL8BZYzMqw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG-2FDASnMBq4sRJfEAIUZaW0goJKvUW_Aqs1Cbb3ayq8tP4dcw4ya5QRW-9JrYTzcMz9jw-gJe5pxYqyvDUpHhAMSLmWjhSPKeMrbSKQsv8g8Ns9yj9fCyP1-DPUAtDaZXDnhg2atdYuiPfFhTfQVueiO2qT4v4ujN-Nz3jhCBFkdYBTqMTkX1_cY7Ht_nbvR3k9Sshxh-_f9jlPcIAt0kuW54Y77yXWa5kmsUutS4tvIi9lZGpXI7mTUcuiSIjC201OgOO4mjoQ6U-s7l1Ca57A27mCeoJVamPP60a_sYB3CxSuKHkSqV9wU4o2yMAtYhTckREzi1X_xrFS57upShtMH7jO3C791rZ-07M7sKar-_BxkEfl78P02_nkzZkZTKkDeEu6BmbaTdpqlmXq33BtOnS7tgk3GP4OTtp6p-cTANrFi1yAR81FaNo_-KUzye_vWO_0Fq2DUUXKF2WWUI-qptT_QCOroXSD2G9bmr_GFhqKuWrQlbaqRD1U0YoKVxW2EzKRI0gHohZ2r7ROeFtnJTLFs2BASUyoAwMKHHO6-Wcadfm48rRWwOPyl7l5-VKQEfwYvkalZVopGvfLGgMQSCisxCN4FHH2-XnEnQd8exWjODNwOzV4v__l82r_-U5bKCalF_2DvefwC1BMhcKKbdgvZ0t_FP0qFrzLIgugx_XrSt_AS8SMEg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Switching+monopolar+radiofrequency+ablation+improves+long-term+outcomes+of+medium-sized+hepatocellular+carcinoma&rft.jtitle=European+radiology&rft.au=Lin%2C+Chen-Chun&rft.au=Lui%2C+Kar-Wai&rft.au=Chen%2C+Wei-Ting&rft.au=Hsieh%2C+Yi-Chung&rft.date=2021-11-01&rft.issn=0938-7994&rft.eissn=1432-1084&rft.volume=31&rft.issue=11&rft.spage=8649&rft.epage=8661&rft_id=info:doi/10.1007%2Fs00330-021-07729-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00330_021_07729_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0938-7994&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0938-7994&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0938-7994&client=summon |